TLR9 and HIV infectious disease: On the other hand, the TLR9 agonist Lefitolimod in combination with neutralizing antibodies is in phase II trials studying its effectiveness in conferring reservoir reduction in HIV infection (NCT03837756) after phase I demonstrated its safety and effectiveness in improving both innate and adaptive immunity in HIV-1 infected patients (277).